Effectiveness of Pegylated Interferon Alpha-2a in Post-Uveitic Macular Edema Previously Responding to Non-Pegylated Interferon

References

• Okhravi N, Lightman S. Cystoid macular edema in uveitis. Ocul Immunol Inflamm. 2003;11(1):29–38. doi:10.1076/ocii.11.1.29.15582.
   PubMed Web of Science ®Google Scholar
• Lardenoye CWTA, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113(8):1446–1449. doi:10.1016/j.ophtha.2006.03.027.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Koetter I, Guenaydin I, Stuebiger N, Zierhut M. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina. 2006;26(7):786–791. doi:10.1097/01.iae.0000244265.75771.71.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Kotter I, Gunaydin I, Stubiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. British J Ophthalmol. 2009;93(7):906–913. doi:10.1136/bjo.2008.153874.
   PubMed Web of Science ®Google Scholar
• Lewczuk N, Zdebik A, Bogusławska J. Interferon alpha 2a and 2b in ophthalmology: a review. J Int Cytokine Res. 2019;39(5):259–272. doi:10.1089/jir.2018.0125.
   PubMed Web of Science ®Google Scholar
• De Simone L, Sangiovanni A, Aldigeri R, et al. Interferon alpha-2a treatment for post-uveitic refractory macular edema. Ocul Immunol Inflammation. 2020;28(2):322–328. doi:10.1080/09273948.2019.1589526.
   PubMed Web of Science ®Google Scholar
• Qian Z, Fardeau C, Cardoso JN, Jellab B, Fan X, LeHoang P. Effect of interferon α2a in cystoid macular edema due to intraocular infection. Eur J Ophthalmol. 2015;25(5):431–436. doi:10.5301/ejo.5000591.
   PubMed Web of Science ®Google Scholar
• Oray M, Onal S, Uludag G, Akbay AK, Tugal-Tutkun I. Interferon alpha for the treatment of cystoid macular edema associated with presumed ocular tuberculosis. J Ocul Pharmacol Ther. 2017;33(4):304–312. doi:10.1089/jop.2016.0097.
   PubMed Web of Science ®Google Scholar
• Aksu-Ceylan N, Cebeci Z, Altinkurt E, Kir N, Oray M, Tugal-Tutkun I. Interferon alpha-2a for the treatment of cystoid macular edema secondary to acute retinal necrosis. Ocul Immunol Inflammation. 2021;30(7–8):1788–1797. doi:10.1080/09273948.2021.1957121.
   PubMed Web of Science ®Google Scholar
• Gillies MC, Su T. Interferon-α 2b enhances barrier function of bovine retinal microvascular endothelium in vitro. Microvasc Res. 1995;49(3):277–288. doi:10.1006/mvre.1995.1024.
   PubMed Web of Science ®Google Scholar
• Stiefel HC, Kopplin LJ, Albini T, Chang M, Vegunta S, Suhler EB. Treatment of refractory cystoid macular edema with pegylated interferon alfa-2a: a retrospective chart review. Ocul Immunol Inflammation. 2021;29(3):566–571. doi:10.1080/09273948.2019.1687729.
   PubMed Web of Science ®Google Scholar
• Couret C, Servant M, Lebranchu P, Hamidou M, Weber M. Efficacy and safety of Interferon alpha 2a and pegylated interferon alpha 2a in inflammatory macular Edema. Ocul Immunol Inflammation. 2020;28:329–336. doi:10.1080/09273948.2019.1604001.
   PubMed Web of Science ®Google Scholar
• Duan J, Wang Y, Liu D, Ma J. Induction of Vogt-Koyanagi-Harada disease by interferon-alpha and ribavirin treatment in patients with hepatitis C: a case report and review of the literature. Ocul Immunol Inflamm. 2019;27(2):229–234. doi:10.1080/09273948.2017.1373827.
   PubMed Web of Science ®Google Scholar
• Kasahara A, Hiraide A, Tomita N, et al. Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C. J Gastroenterol. 2004;39(11):1106–1109. doi:10.1007/s00535-004-1452-4.
   PubMed Web of Science ®Google Scholar
• Kato A, Ishihara M, Mizuki N. Interferon-induced sarcoidosis with uveitis as the initial symptom: a case report and review of the literature. J Med Case Rep. 2021;15(1). doi:10.1186/s13256-021-03181-x.
   Google Scholar
• Doycheva D, Deuter C, Stuebiger N, Zierhut M. Interferon-alpha-associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol. 2009;247(5):675–680. doi:10.1007/s00417-008-1002-5.
   PubMed Web of Science ®Google Scholar
• Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Plskova J, Greiner K, Forrester JV. Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol. 2007;144(1):55–61.e2. doi:10.1016/j.ajo.2007.03.050.
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91(3):335–339. doi:10.1136/bjo.2006.101550.
   PubMed Web of Science ®Google Scholar
• Butler NJ, Suhler EB, Rosenbaum JT. Interferon alpha 2b in the treatment of uveitic cystoid macular edema. Ocul Immunol Inflamm. 2012;20(2):86–90. doi:10.3109/09273948.2011.645989.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Zierhut M, Möhle A, Vonthein R, Stöbiger N, Kötter I. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet’s disease. Arthritis Rheumatism. 2010;62(9):2796–2805. doi:10.1002/art.27581.
   PubMed Web of Science ®Google Scholar
• Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with behçet disease. Am J Ophthalmol. 2008;146(6):837–844. doi:10.1016/j.ajo.2008.08.038.
   PubMed Web of Science ®Google Scholar
• Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs. 2008;22(5):315–329. doi:10.2165/00063030-200822050-00004.
   PubMed Web of Science ®Google Scholar
• Calvaruso V, Mazza M, Almasio PL. Pegylated-interferon-α 2a in clinical practice: how to manage patients suffering from side effects. Expert Opin Drug Saf. 2011;10(3):429–435. doi:10.1517/14740338.2011.559161.
   PubMed Web of Science ®Google Scholar
• Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol. 1993;111(3):350–356. doi:10.1001/archopht.1993.01090030068041.
   PubMedGoogle Scholar
• Purvin VA. Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol. 1995;113(8):1041–1044. doi:10.1001/archopht.1995.01100080093034.
   PubMedGoogle Scholar
• Gonçalves LL, Farias AQ, Gonçalves PL, D’amico EA, Carrilho FJ. Branch retinal vein thrombosis and visual loss probably associated with pegylated interferon therapy of chronic hepatitis C. World J Gastroenterol. 2006;12(28):4602–4603. doi:10.3748/wjg.v12.i28.4602.
   PubMed Web of Science ®Google Scholar
• Ayaki M. Development of neovascular glaucoma in the course of interferon alfa therapy for hepatitis type C. Br J Ophthalmol. 1994;78(3):238. doi:10.1136/bjo.78.3.238-a.
   PubMed Web of Science ®Google Scholar